drugset / Trial / NCT00006216
Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
Treatment
Summary
RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus ganciclovir in treating patients who have stage I, stage II, or stage III malignant mesothelioma.
Timeline
- Start
- 1997-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganciclovir | Small molecule | — | Intravenous |
| Subject | PA-1-STK | Vaccine | — | Other |